GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK plc (LSE/NYSE: GSK) today announced that it has reached agreements with 10 plaintiff firms who together represent 93% (approximately 80,000) of the Zantac (ranitidine) state court product ...

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...

Under the agreement, whose terms are confidential, GSK will make an "aggregate payment of up to $2.2 billion" to resolve ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...